S 2336 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Halting the Epidemic of Addiction and Loss Act of 2025
To ensure references to opioid overdose reversal agents in certain grant programs of the Department of Health and Human Services are not limited to naloxone.
Summary
- Directs the Department of Health and Human Services to ensure that references to opioid overdose reversal drugs in regulations and guidance for opioid misuse grant programs include all FDA-approved opioid overdose reversal drugs, not just naloxone.
- Requires HHS to update all existing regulations and guidance references to opioid overdose reversal drugs within 1 year to include any FDA-approved opioid overdose reversal drug.
- Applies these requirements to the State and Tribal opioid response grant programs and the substance use disorder prevention grant programs under HHS.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
-
![Sen. Cornyn, John [R-TX]](https://media.civicgate.org/people/d/politicians/C001056.thumb.jpg)
Sen. Cornyn, John (R-TX)
1 cosponsor
-
![Sen. Hassan, Margaret Wood [D-NH]](https://media.civicgate.org/people/d/politicians/H001076.thumb.jpg)
Sen. Hassan, Margaret Wood (D-NH)
Actions (2)
- Jul 17, 2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. · senate
- Jul 17, 2025 Introduced in Senate
Full text
IN THE SENATE OF THE UNITED STATES
July 17, 2025
Mr. Cornyn (for himself and Ms. Hassan) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions
A BILL
To ensure references to opioid overdose reversal agents in certain grant programs of the Department of Health and Human Services are not limited to naloxone.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Halting the Epidemic of Addiction and Loss Act of 2025”.
SEC. 2. REFERENCES TO OPIOID OVERDOSE REVERSAL AGENTS IN HHS GRANT PROGRAMS.
(a) In General.—The Secretary of Health and Human Services shall ensure that, as appropriate, whenever the Department of Health and Human Services issues a regulation or guidance for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal drug (such as a reference to naloxone) is inclusive of any opioid overdose reversal drug that has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for emergency treatment of a known or suspected opioid overdose.
(b) Existing References.—
(1) Update.—Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall update all references described in paragraph (2) to be inclusive of any opioid overdose reversal drug that has been approved or otherwise authorized for use by the Food and Drug Administration.
(2) References.—A reference described in this paragraph is any reference to an opioid overdose reversal drug (such as naloxone) in any regulation or guidance of the Department of Health and Human Services that—
(A) was issued before the date of enactment of this Act; and
(B) is included in—
(i) the grant program for State and Tribal response to opioid use disorders under section 1003 of the 21st Century Cures Act (42 U.S.C. 290ee-3a) (commonly referred to as “State Opioid Response Grants” and “Tribal Opioid Response Grants”); or
(ii) the grant program for priority substance use disorder prevention needs of regional and national significance under section 516 of the Public Health Service Act (42 U.S.C. 290bb-22). <all>
Comments